CLARITY 12-Month Study

February 22, 2024

CLARITY Study Shows Positive Long-Term Results from Study on Chronic Rhinitis Treatment. Click the button below to read more.

‍

See Full Article See Full Article

Share this post

Our Newsletter

Subscribe to our newsletter to stay informed on the latest news and updates

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Related Content

Neurent Medical Announces Expanded Access Following Cigna Policy Update for NEUROMARK®

We’re proud to share that Cigna Healthcare has officially removed CPT 31242 posterior nasal nerve ablation using radiofrequency from its Experimental & Investigational (E&I) list, effective September 15, 2025.

Neurent Medical Announces 510(k) Clearance of its Next Generation NEUROMARK® System

Neurent Medical has received FDA 510(k) clearance for its next-generation NEUROMARK® System, a minimally invasive device that provides ENT specialists with enhanced control, real-time feedback, and treatment confirmation for chronic rhinitis. Developed in collaboration with leading ENT experts, the updated system is now positioned for broader U.S. availability to meet growing demand.

New Data show NEUROMARK® Chronic Rhinitis Treatment Offers Significant Symptom Improvements

3-month results from the CLARITY Study Show the NEUROMARK® System provides safe and effective treatment for patients with Chronic Rhinitis.

Clinical Studies

•

View ALl Resources